241 related articles for article (PubMed ID: 9626808)
1. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
Patel SR; Vadhan-Raj S; Burgess MA; Plager C; Papadopolous N; Jenkins J; Benjamin RS
Am J Clin Oncol; 1998 Jun; 21(3):317-21. PubMed ID: 9626808
[TBL] [Abstract][Full Text] [Related]
2. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
4. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
[TBL] [Abstract][Full Text] [Related]
6. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Leyvraz S; Zweifel M; Jundt G; Lissoni A; Cerny T; Sessa C; Fey M; Dietrich D; Honegger HP;
Ann Oncol; 2006 Apr; 17(4):646-51. PubMed ID: 16500907
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Leyvraz S; Herrmann R; Guillou L; Honegger HP; Christinat A; Fey MF; Sessa C; Wernli M; Cerny T; Dietrich D; Pestalozzi B;
Br J Cancer; 2006 Nov; 95(10):1342-7. PubMed ID: 17031396
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
Reichardt P; Tilgner J; Hohenberger P; Dörken B
J Clin Oncol; 1998 Apr; 16(4):1438-43. PubMed ID: 9552049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
